Sign in or create an account to add this stock to your watchlist.
Immunovaccine Inc., a clinical-stage company, together with its subsidiaries, develops products based on its platform and products with a primary focus on T cell activating therapies for cancer. The company's DepoVax platform is a patented formulation that provides controlled and prolonged exposure of antigens and adjuvant to the immune system. It has two T cell activation therapies for cancer through Phase I human clinical trial and is conducting a Phase Ib study with Incyte Corporation for lead cancer therapy; and DPX-Survivac, as a combination therapy for ovarian cancer. The company is also conducting a Phase II study for DPX-Survivac in ovarian and lymphoma. In addition, it is developing DPX-RSV, a vaccine candidate, which has completed a Phase I clinical trial for respiratory syncytial virus, as well as has clinical projects to assess the DepoVax to address malaria and the Zika virus; DPX-E7 an investigational immunotherapy that targets a viral protein in human papillomavirus (HPV) known as E7. The company has research collaborations with companies and research organizations, including Merck, Incyte Corporation, and Leidos Inc, as well as with Zoetis. The company was formerly known as Rhino Resources Inc. and changed its name to Immunovaccine Inc. in September 2009. Immunovaccine Inc. was founded in 2000 and is based in Halifax, Canada.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolTSE:IMV
CUSIPN/A
Phone+1-902-4921819
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
EmployeesN/A
Outstanding Shares137,107,000
IMV (TSE:IMV) Frequently Asked Questions
What is IMV's stock symbol?
IMV trades on the Toronto Stock Exchange (TSX) under the ticker symbol "IMV."
How were IMV's earnings last quarter?
Imv Inc (TSE:IMV) posted its earnings results on Tuesday, March, 20th. The company reported ($0.04) earnings per share (EPS) for the quarter. View IMV's Earnings History.
When is IMV's next earnings date?
What price target have analysts set for IMV?
1 analysts have issued 1-year target prices for IMV's stock. Their predictions range from C$9.60 to C$9.60. On average, they expect IMV's share price to reach C$9.60 in the next year. View Analyst Ratings for IMV.
Who are some of IMV's key competitors?
Some companies that are related to IMV include Genfit (GNFTF), Mesoblast (MSB), Theratechnologies (TH), Mesoblast (MEOBF), MediGene (MDG1), Oxford BioMedica (OXB), BioTime (BTX), Resverlogix (RVX), 22nd Century Group (XXII), Protalix BioTherapeutics (PLX), Neptune Wellness Solutions (NEPT), Monash IVF Gr (MVF), Horizon Discovery (HZD), Bionomics (BNO) and Adherex Technologies (FRX).
Who are IMV's key executives?
IMV's management team includes the folowing people:
- Mr. Frederic Ors, CEO & Director (Age 44)
- Dr. Gabriela Nicola Rosu M.D., Chief Medical Officer
- Mr. Leeladhar Sammatur, VP of Product Devel. & Manufacturing
- Dr. Marc Mansour Ph.D., MBA, Consultant (Age 45)
- Mr. Pierre Labbé, Chief Financial Officer (Age 53)
Has IMV been receiving favorable news coverage?
Press coverage about IMV stock has been trending somewhat negative recently, Accern Sentiment reports. The research group identifies positive and negative press coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. IMV earned a news sentiment score of -0.08 on Accern's scale. They also assigned news headlines about the company an impact score of 44.43 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.
How do I buy shares of IMV?
Shares of IMV and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is IMV's stock price today?
One share of IMV stock can currently be purchased for approximately C$8.66.
How big of a company is IMV?
IMV has a market capitalization of C$255.47 million.
How can I contact IMV?
IMV's mailing address is 1344 Summer Street, Suite 412, HALIFAX, NS B3H 0A8, Canada. The company can be reached via phone at +1-902-4921819.
MarketBeat Community Rating for IMV (IMV)
MarketBeat's community ratings are surveys of what our community members think about IMV and other stocks. Vote "Outperform" if you believe IMV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IMV will underperform the S&P 500 over the long term. You may vote once every thirty days.
IMV (TSE:IMV) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
1 Wall Street analysts have issued ratings and price targets for IMV in the last 12 months. Their average twelve-month price target is C$9.60, suggesting that the stock has a possible upside of 10.85%. The high price target for IMV is C$9.60 and the low price target for IMV is C$9.60. There are currently 1 buy rating for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | N/A | N/A | N/A |
| Consensus Rating Score: | 3.00 | N/A | N/A | N/A |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | C$9.60 | N/A | N/A | N/A |
| Price Target Upside: | 10.85% upside | N/A | N/A | N/A |
IMV (TSE:IMV) Consensus Price Target History
IMV (TSE:IMV) Analyst Ratings History
Show:
| Date | Brokerage | Action | Rating | Price Target | Details |
|---|
| 5/10/2018 | National Bank Financial | Boost Price Target | Outperform | C$3.00 ➝ C$9.60 |  |
(Data available from 5/20/2016 forward)
IMV (TSE:IMV) Earnings History and Estimates Chart
IMV (TSE IMV) Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 8/14/2018 | | | | | | | | |
| 3/20/2018 | Q4 2017 | | C($0.04) | | | View | N/A | |
| 11/9/2017 | Q3 2017 | | C($0.02) | | | View | N/A | |
| 8/8/2017 | Q2 2017 | C($0.02) | C($0.02) | | | View | N/A | |
| 5/10/2017 | Q1 2017 | C($0.02) | C($0.02) | | | View | N/A | |
| 3/30/2017 | Q4 2016 | C($0.02) | C($0.03) | | | View | N/A | |
| 11/8/2016 | Q3 2016 | C($0.02) | C($0.02) | | | View | N/A | |
| 8/9/2016 | Q2 2016 | C($0.02) | C($0.01) | C$0.10 million | C$0.07 million | View | N/A | |
| 5/10/2016 | Q1 2016 | C($0.02) | C($0.02) | C$0.10 million | C$0.07 million | View | N/A | |
| 3/29/2016 | Q4 2015 | | C($0.02) | | C$0.07 million | View | N/A | |
| 11/12/2015 | Q3 2015 | | C($0.02) | | C$0.07 million | View | N/A | |
| 8/12/2015 | Q2 2015 | | C($0.03) | | | View | N/A | |
| 5/12/2015 | Q1 2015 | | C($0.02) | | | View | N/A | |
| 3/20/2015 | Q4 2014 | | C($0.02) | | | View | N/A | |
| 11/14/2014 | Q3 2014 | | C($0.02) | | | View | N/A | |
| 8/15/2014 | Q2 2014 | | C($0.02) | | | View | N/A | |
| 5/28/2014 | Q1 2014 | | C($0.02) | | | View | N/A | |
| 3/17/2014 | Q4 2013 | | C($0.02) | | | View | N/A | |
| 11/29/2013 | Q3 2013 | C($0.03) | C($0.02) | | | View | N/A | |
| 8/29/2013 | Q2 2013 | C($0.03) | C($0.01) | | | View | N/A | |
| 5/16/2013 | Q1 2013 | C($0.03) | C($0.02) | | | View | N/A | |
(Earnings results data provided by Zacks Investment Research)
IMV (TSE:IMV) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
IMV (TSE IMV) Insider Trading and Institutional Ownership History
IMV (TSE IMV) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/26/2018 | Alfred Smithers | Director | Buy | 55,000 | C$1.80 | C$99,000.00 | | |
| 3/22/2018 | Andrew J Sheldon | Director | Buy | 9,500 | C$1.99 | C$18,905.00 | | |
| 2/13/2018 | Frederic Ors | Director | Buy | 16,000 | C$1.88 | C$30,080.00 | | |
| 2/12/2018 | Pierre Labbé | Insider | Buy | 20,800 | C$1.89 | C$39,312.00 | | |
| 2/5/2018 | Alfred Smithers | Director | Buy | 10,000 | C$2.00 | C$20,000.00 | | |
| 2/2/2018 | Alfred Smithers | Director | Buy | 10,000 | C$2.05 | C$20,500.00 | | |
| 1/24/2018 | Alfred Smithers | Director | Buy | 33,600 | C$2.09 | C$70,224.00 | | |
(Data available from 1/1/2013 forward)
IMV (TSE IMV) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | IMV Inc. (Formerly Immunovaccine Inc.) Announces Q1 2018 Financial Results
finance.yahoo.com - May 15 at 8:34 AM |
 | ImmunoVaccine (IMV) Price Target Raised to C$9.60
www.americanbankingnews.com - May 10 at 5:57 PM |
| IMV Inc. – Change of ticker on OTCQX from IMMVF to IMMVD
finance.yahoo.com - May 10 at 3:23 PM |
| IMV Inc. Commences Trading on the TSX and OTCQX Post-Reverse Stock Split
finance.yahoo.com - May 10 at 8:21 AM |
 | Immunovaccine Aims for NASDAQ, Implements Reverse Split and Name Change to IMV
www.baystreet.ca - May 3 at 3:22 PM |
 | Immunovaccine reverse split shares 1:3.2, application filed for Nasdaq listing, name changed to IMV
seekingalpha.com - May 3 at 8:22 AM |
| Immunovaccine Inc. Has Applied to List its Common Shares on Nasdaq, Announces Reverse Stock Split
finance.yahoo.com - May 3 at 8:22 AM |
| Immunovaccine Shareholders Approve Share Consolidation at 99.85%
finance.yahoo.com - May 2 at 8:13 AM |
| Today’s Research Reports on Fennec Pharmaceuticals, Aptose Biosciences, TSO3 and ImmunoVaccine
finance.yahoo.com - May 2 at 8:13 AM |
| Stonegate Capital Partners Initiates Coverage on ImmunoVaccine, Inc. (TSX: IMV)
finance.yahoo.com - May 1 at 8:18 AM |
| Alfred Smithers Buys 55,000 Shares of ImmunoVaccine Inc. (IMV) Stock
www.americanbankingnews.com - April 29 at 7:16 PM |
 | Researchers Will Present New Data from the Ongoing Phase 1b/2 Advanced Ovarian Cancer Study in Collaboration with Incyte
globenewswire.com - April 26 at 8:10 AM |
| Immunovaccine and Incyte Expand Clinical Collaboration Evaluating Combination Immunotherapies in Advanced Recurrent Ovarian Cancer
finance.yahoo.com - April 24 at 8:10 AM |
| Immunovaccine Announces Leading Independent Proxy Advisory Firms Recommend Voting for Share Consolidation Related to Potential Nasdaq Listing
finance.yahoo.com - April 17 at 7:42 AM |
| Preclinical Data Presented at AACR Highlight the Novel Mechanism of Action Underscoring the Company’s T cell-Activating Technology
globenewswire.com - April 16 at 3:21 PM |
| Research Reports on Aurinia Pharma, Immunovaccine, IntelliPharmaCeutics International, and OrganiGram Holdings
finance.yahoo.com - April 12 at 7:37 AM |
| Immunovaccine Files Circular for Annual and Special Meeting of Shareholders
globenewswire.com - April 5 at 9:09 AM |
| Immunovaccine Announces Initiation of Patient Dosing in Investigator-Sponsored Phase 2 Clinical Trial of Its Lead Candidate ...
globenewswire.com - March 28 at 7:17 AM |
| Immunovaccine Announces Initiation of Patient Dosing in Investigator-Sponsored Phase 2 Clinical Trial of Its Lead Candidate DPX-Survivac Used in Combination with Pembrolizumab in Patients with DLBCL
finance.yahoo.com - March 28 at 7:17 AM |
| Immunovaccine Announces Webcast of R&D Update and Investor Event
finance.yahoo.com - March 27 at 7:19 AM |
| FY2018 EPS Estimates for ImmunoVaccine Inc. Reduced by National Bank Financial (IMV)
www.americanbankingnews.com - March 26 at 1:24 AM |
| ImmunoVaccine Inc. (IMV) Director Andrew J. Sheldon Acquires 9,500 Shares
www.americanbankingnews.com - March 22 at 1:37 PM |
| Immunovaccine to Host Investor Event on April 10, 2018 in New York City - GlobeNewswire (press release)
globenewswire.com - March 15 at 3:20 PM |
| Immunovaccine to Host Investor Event on April 10, 2018 in New York City
finance.yahoo.com - March 14 at 6:38 AM |
| Immunovaccine Chief Medical Officer Dr. Gabriela Rosu to Present at the Oncology Meeting Innovations (OMI) Annual Summit on Hematologic Malignancies
finance.yahoo.com - March 9 at 6:40 AM |
| Fonds de solidarité FTQ Invests $5.75 Million In Immunovaccine Share Capital
finance.yahoo.com - February 16 at 3:15 PM |
| Immunovaccine Announces Closing of $14.375 million Bought Deal Offering with Over-allotment option exercised in full
finance.yahoo.com - February 15 at 9:51 AM |
| ImmunoVaccine Inc. (IMV) Director Buys C$30,080.00 in Stock
www.americanbankingnews.com - February 13 at 6:46 PM |
| Insider Buying: ImmunoVaccine Inc. (IMV) Insider Acquires 20,800 Shares of Stock
www.americanbankingnews.com - February 13 at 12:30 PM |
| Insider Buying: ImmunoVaccine Inc. (IMV) Director Purchases 10,000 Shares of Stock
www.americanbankingnews.com - February 6 at 7:00 PM |
| ImmunoVaccine Inc. (IMV) Director Purchases C$20,500.00 in Stock
www.americanbankingnews.com - February 6 at 7:00 PM |
| Insider Buying: ImmunoVaccine Inc. (IMV) Director Acquires 33,600 Shares of Stock
www.americanbankingnews.com - January 26 at 12:26 PM |
| Immunovaccine Receives an Extension to the Maturity Date of its $5M Loan Until 2020 - GlobeNewswire (press release)
globenewswire.com - October 20 at 12:16 AM |
| Immunovaccine Receives an Extension to the Maturity Date of its $5M Loan Until 2020
finance.yahoo.com - October 18 at 2:33 AM |
| Immunovaccine Researchers to Present Data at Two Upcoming Conferences that Demonstrate the Broad Applicability of the Company’s DepoVax™-based Programs
finance.yahoo.com - October 5 at 9:15 AM |
| New Technology Could Help Detect The Leading Cause Of Strokes
www.baystreet.ca - September 14 at 6:26 AM |
| Daily Coverage on Healthcare Stocks, Oncolytics Biotech, Aurinia Pharma, Immunovaccine, and IntelliPharmaCeutics International
finance.yahoo.com - September 6 at 6:23 AM |
| Immunovaccine Announces Achievement of Milestones in Collaboration with Zoetis to Develop Veterinary Vaccines
finance.yahoo.com - August 31 at 7:52 PM |
 | Immunovaccine to Present at 19th Annual Rodman & Renshaw ... - Nasdaq
www.nasdaq.com - August 31 at 6:14 AM |
| Immunovaccine to Present at 19th Annual Rodman & Renshaw Global Investment Conference
finance.yahoo.com - August 31 at 6:14 AM |
| ImmunoVaccine, Inc. breached its 50 day moving average in a Bullish Manner : IMV-CA : August 9, 2017
finance.yahoo.com - August 9 at 8:06 PM |
| ImmunoVaccine Inc. (TSE:IMV) PT Set at C$2.50 by National Bank Financial
www.americanbankingnews.com - August 9 at 3:58 PM |
| Immunovaccine Announces Financial Results for Quarter Ended June 30, 2017
finance.yahoo.com - August 8 at 7:32 PM |
| ImmunoVaccine, Inc. – Value Analysis (TORONTO:IMV) : July 31, 2017
finance.yahoo.com - July 31 at 7:17 PM |
| Insider Buying: ImmunoVaccine Inc. (TSE:IMV) Insider Buys 26,825 Shares of Stock
www.americanbankingnews.com - July 31 at 1:25 PM |
| Pierre Labbé Acquires 25,000 Shares of ImmunoVaccine Inc. (IMV) Stock
www.americanbankingnews.com - July 21 at 1:19 PM |
| ImmunoVaccine, Inc. breached its 50 day moving average in a Bullish Manner : IMV-CA : July 14, 2017
finance.yahoo.com - July 15 at 2:51 AM |
| Immunovaccine Achieves Breakthrough in Support of Developing Personalized Cancer Immunotherapies
finance.yahoo.com - July 13 at 3:13 AM |
 | McCain: North Korea Is First ‘Real Test’ of Trump’s Presidency
www.nbcnews.com - April 16 at 10:15 AM |
 | Syrian jets take off from air base hit by US
abcnews.go.com - April 9 at 10:32 AM |
IMV (TSE:IMV) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
IMV (TSE IMV) Stock Chart for Sunday, May, 20, 2018
Loading chart…
